Eli Lilly & Co
LLY- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000059478
In the last 90 days, Eli Lilly & Co insiders filed 0 open-market purchases and 3 sales; 4,643 institutions reported holding it in 13F filings for Q2 2026, worth $942.7B in total; 4 superinvestors hold it, including ARK Invest and Soros Fund Management.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Eli Lilly & Co insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 3 filings
- 3 insiders, $16.0M in total
- Insiders trading
- 3
- Net value
- −$16.0M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Eli Lilly & Co, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Sulzberger Gabrielle | Director | 3,012 | Sep 22, 2026 | 12 |
| Luciano Juan R | Director | 16,957 | Sep 22, 2026 | 12 |
| Fyrwald J Erik | Director | 75,536 | Sep 22, 2026 | 12 |
| Alvarez Ralph | Director | 55,838 | Sep 22, 2026 | 12 |
| Seymour Melissa | EVP, Global Quality | 1,038 | Sep 11, 2026 | 2 |
| Hernandez Edgardo | EVP & Pres., Mfg. Operations | 46,083 | Sep 4, 2026 | 3 |
| Dozier Eric | EVP, Chief People Officer | 14,239 | Sep 4, 2026 | 4 |
| Jonsson Patrik | EVP & President, LLY Int'l | 54,147 | Aug 18, 2026 | 3 |
| Zakrowski Donald A | SVP, Finance, & CAO | 1,526 | Aug 11, 2026 | 4 |
| Hakim Anat | EVP, GC & Secretary | 11,875Indirect | Aug 10, 2026 | 3 |
| Yuffa Ilya | EVP&Pres, LLY USA&Global Capab | 29,804 | Jun 11, 2026 | 3 |
| Lilly Endowment Inc | Other: Former 10% Shareholder | 91,881,150 | May 7, 2026 | 34 |
| Montarce Lucas | EVP & CFO | 16,258 | Feb 18, 2026 | 2 |
| Custer Kenneth L. | EVP & President, Card Met Hlth | 10,141 | Feb 18, 2026 | 2 |
| Brown Adrienne S | EVP, President LLY Imm | 5,142 | Feb 18, 2026 | 2 |
| Rau Diogo | EVP & CIDO | 26,397 | Feb 12, 2026 | 2 |
| Ricks David A | President, Chair, and CEO | 571,715 | Feb 11, 2026 | 3 |
| Van Naarden Jacob | EVP,Pres LLY Oncology&HdCorpBD | 26,627 | Feb 11, 2026 | 2 |
| Skovronsky Daniel | EVP, CS&PO & Pres. LRL | 160,072 | Feb 11, 2026 | 3 |
| Hedley Mary Lynne | Director | 2,253 | Dec 16, 2025 | 3 |
| Moeller Jon R | Director | 304 | Nov 18, 2025 | 1 |
| Baicker Katherine | Director | 23,503 | Nov 18, 2025 | 1 |
| Kaelin William G Jr | Director | 21,837 | Nov 18, 2025 | 1 |
| Jackson Jamere | Director | 9,635 | Nov 18, 2025 | 1 |
| Johnson Kimberly H | Director | 3,265 | Nov 18, 2025 | 1 |
| White Anne E. | EVP & Pres, Lilly Neuroscience | 74,210 | Feb 12, 2025 | 0 |
| Walker Karen | Director | 6,249 | Nov 20, 2024 | 0 |
| Norton Johna | EVP, Global Quality | 25,428 | Jun 3, 2024 | 0 |
| Ashkenazi Anat | EVP & CFO | 42,330 | Feb 14, 2024 | 0 |
| Weems Alonzo | EVP, ERM & CECO | 7,951 | Feb 14, 2024 | 0 |
| Runge Marschall S | Director | 16,593 | Nov 21, 2023 | 0 |
| Tai Jackson P | Director | 63,524 | Apr 19, 2023 | 0 |
| Pusey Leigh Ann | EVP, Corp. Affairs & Comm. | 31,641 | Feb 14, 2023 | 0 |
| Mason Michael B | EVP & Pres., Lilly Diabetes | 39,284 | Feb 14, 2023 | 0 |
| Fry Stephen F | SVP, HR & Diversity | 152,631 | Feb 11, 2022 | 0 |
| Eskew Michael L | Director | 45,080 | Nov 17, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 15, 2022 (view filing) | Mar 14 | 1 day | Lilly Endowment Inc10% Owner | SSale | −173.1K | $269.38 | −$46.6M | −0.2%106.9M after | 2 lots |
| Mar 14, 2022 (view filing) | Mar 11 | 3 days | Lilly Endowment Inc10% Owner | SSale | −21.8K | $269.05 | −$5.88M | 0.0%107.0M after | |
| Mar 11, 2022 (view filing) | Mar 10 | 1 day | Lilly Endowment Inc10% Owner | SSale | −185.0K | $266.44 | −$49.3M | −0.2%107.0M after | 2 lots |
| Mar 10, 2022 (view filing) | Mar 9 | 1 day | Lilly Endowment Inc10% Owner | SSale | −20.0K | $266.52 | −$5.34M | 0.0%107.2M after | 2 lots |
| Mar 7, 2022 (view filing) | Mar 4 | 3 days | Lilly Endowment Inc10% Owner | SSale | −210.0K | $262.25 | −$55.1M | −0.2%107.3M after | 4 lots |
| Mar 7, 2022 (view filing) | Mar 1 | 6 daysLate | Runge Marschall SDirector | PPurchase | +202 | $246.78 | +$49.8K | +1.3%15.4K after | |
| Mar 3, 2022 (view filing) | Mar 1 | 2 days | Jonsson PatrikSVP&Pres, LLY Imm, LLY USA&CCO | SSale | −675 | $247.56 | −$167.1K | −2.1%32.0K after | |
| Feb 28, 2022 (view filing) | Feb 25 | 3 days | Zakrowski Donald AChief Accounting Officer | SSale | −1.66K | $243.84 | −$404.8K | −18.6%7.27K after | |
| Feb 17, 2022 (view filing) | Feb 15-16 | 2 days | Yuffa IlyaSVP & President, LLY Int'l | SSale | −2.00K | $240.02 | −$480.0K | −14.7%11.6K after | 2 lots |
| Jan 3, 2022 (view filing) | Dec 30, 2021 | 4 days | Lilly Endowment Inc10% Owner | SSale | −3.61K | $279.55 | −$1.01M | 0.0%107.5M after | |
| Dec 28, 2021 (view filing) | Dec 27 | 1 day | Lilly Endowment Inc10% Owner | SSale | −3.57K | $279.53 | −$997.9K | 0.0%107.5M after | |
| Dec 17, 2021 (view filing) | Dec 16 | 1 day | Lilly Endowment Inc10% Owner | SSale | −177.6K | $280.21 | −$49.8M | −0.2%107.5M after | 4 lots |
| Dec 16, 2021 (view filing) | Dec 15 | 1 day | Lilly Endowment Inc10% Owner | SSale | −205.0K | $271.90 | −$55.7M | −0.2%107.6M after | 9 lots |
| Nov 5, 2021 (view filing) | Nov 4 | 1 day | Lilly Endowment Inc10% Owner | SSale | −195.0K | $268.82 | −$52.4M | −0.2%107.9M after | 6 lots |
| Oct 29, 2021 (view filing) | Oct 28 | 1 day | Lilly Endowment Inc10% Owner | SSale | −178.6K | $253.24 | −$45.2M | −0.2%108.0M after | 5 lots |
| Oct 28, 2021 (view filing) | Oct 27 | 1 day | Lilly Endowment Inc10% Owner | SSale | −21.4K | $252.33 | −$5.39M | 0.0%108.2M after | |
| Aug 19, 2021 (view filing) | Aug 18 | 1 day | Lilly Endowment Inc10% Owner | SSale | −15.4K | $274.31 | −$4.23M | 0.0%108.2M after | |
| Aug 18, 2021 (view filing) | Aug 17 | 1 day | Lilly Endowment Inc10% Owner | SSale | −3.06K | $274.08 | −$838.7K | 0.0%108.3M after | |
| Aug 10, 2021 (view filing) | Aug 9 | 1 day | Lilly Endowment Inc10% Owner | SSale | −104.7K | $267.50 | −$28.0M | −0.1%108.3M after | 8 lots |
| Aug 9, 2021 (view filing) | Aug 6 | 3 days | Lilly Endowment Inc10% Owner | SSale | −7.60K | $264.05 | −$2.01M | 0.0%108.4M after | |
| Aug 6, 2021 (view filing) | Aug 5 | 1 day | Lilly Endowment Inc10% Owner | SSale | −132.7K | $264.26 | −$35.1M | −0.1%108.4M after | 2 lots |
| Aug 5, 2021 (view filing) | Aug 4 | 1 day | Lilly Endowment Inc10% Owner | SSale | −13.5K | $265.15 | −$3.57M | 0.0%108.5M after | 10 lots |
| Aug 4, 2021 (view filing) | Aug 3 | 1 day | Lilly Endowment Inc10% Owner | SSale | −236.5K | $256.12 | −$60.6M | −0.2%108.5M after | 3 lots |
| Jul 22, 2021 (view filing) | Jul 21 | 1 day | Lilly Endowment Inc10% Owner | SSale | −86.1K | $237.00 | −$20.4M | −0.1%108.8M after | |
| Jul 21, 2021 (view filing) | Jul 20 | 1 day | Lilly Endowment Inc10% Owner | SSale | −15.6K | $237.06 | −$3.70M | 0.0%108.8M after | |
| Jul 15, 2021 (view filing) | Jul 14 | 1 day | Lilly Endowment Inc10% Owner | SSale | −10.8K | $237.02 | −$2.56M | 0.0%108.9M after | |
| Jul 13, 2021 (view filing) | Jul 12 | 1 day | Lilly Endowment Inc10% Owner | SSale | −3.24K | $237.09 | −$767.7K | 0.0%108.9M after | |
| Jul 12, 2021 (view filing) | Jul 9 | 3 days | Lilly Endowment Inc10% Owner | SSale | −109.3K | $237.39 | −$25.9M | −0.1%108.9M after | 2 lots |
| Jul 7, 2021 (view filing) | Jul 6 | 1 day | Lilly Endowment Inc10% Owner | SSale | −210.0K | $235.09 | −$49.4M | −0.2%109.0M after | |
| Jul 6, 2021 (view filing) | Jul 2 | 4 days | Lilly Endowment Inc10% Owner | SSale | −202.1K | $232.94 | −$47.1M | −0.2%109.2M after | 3 lots |